(Q48004902)

7 February 2018

editorial

0 references

title

60 years of metformin use: a glance at the past and a look to the future. (English)

1 reference

7 February 2018

1 reference

Sally M Marshall

1

1 reference

7 February 2018

publication date

3 August 2017

1 reference

7 February 2018

published in

Diabetologia

1 reference

7 February 2018

volume

60

1 reference

7 February 2018

issue

9

1 reference

7 February 2018

page(s)

1561-1565

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1007/s00125-017-4343-y

exact match

0 references

cites work

Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin in patients with type 2 diabetes and kidney disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin and the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin: do we finally have an anti-aging drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin: historical overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

The mechanisms of action of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin: clinical use in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

A new perspective on metformin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin use in pregnancy: promises and uncertainties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Metformin and ageing: improving ageing outcomes beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

The effects of metformin on gut microbiota and the immune system as research frontiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

Repurposing metformin for the prevention of cancer and cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

The pharmacogenetics of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4343-Y

10.1007/S00125-017-4343-Y

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

28776085

1 reference

7 February 2018